Literature DB >> 12167566

Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases.

Kenneth F Ilett1, Brian T Ethell, James L Maggs, Timothy M E Davis, Kevin T Batty, Brian Burchell, Tran Quang Binh, Le Thi Anh Thu, Nguyen Canh Hung, Munir Pirmohamed, B Kevin Park, Geoffrey Edwards.   

Abstract

The aim of this study was to elucidate the metabolic pathways for dihydroartemisinin (DHA), the active metabolite of the artemisinin derivative artesunate (ARTS). Urine was collected from 17 Vietnamese adults with falciparum malaria who had received 120 mg of ARTS i.v., and metabolites were analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS). Human liver microsomes were incubated with [12-(3)H]DHA and cofactors for either glucuronidation or cytochrome P450-catalyzed oxidation. Human liver cytosol was incubated with cofactor for sulfation. Metabolites were detected by HPLC-MS and/or HPLC with radiochemical detection. Metabolism of DHA by recombinant human UDP-glucuronosyltransferases (UGTs) was studied. HPLC-MS analysis of urine identified alpha-DHA-beta-glucuronide (alpha-DHA-G) and a product characterized as the tetrahydrofuran isomer of alpha-DHA-G. DHA was present only in very small amounts. The ratio of the tetrahydrofuran isomer, alpha-DHA-G, was highly variable (median 0.75; range 0.09-64). Nevertheless, alpha-DHA-G was generally the major urinary product of DHA glucuronidation in patients. The tetrahydrofuran isomer appeared to be at least partly a product of nonenzymic reactions occurring in urine and was readily formed from alpha-DHA-G by iron-mediated isomerization. In human liver microsomal incubations, DHA-G (diastereomer unspecified) was the only metabolite found (V(max) 177 +/- 47 pmol min(-1) mg(-1), K(m) 90 +/- 16 microM). Alpha-DHA-G was formed in incubations of DHA with expressed UGT1A9 (K(m) 32 microM, V(max) 8.9 pmol min(-1) mg(-1)) or UGT2B7 (K(m) 438 microM, V(max) 10.9 pmol mg(-1) min(-1)) but not with UGT1A1 or UGT1A6. There was no significant metabolism of DHA by cytochrome-P450 oxidation or by cytosolic sulfotransferases. We conclude that alpha-DHA-G is an important metabolite of DHA in humans and that its formation is catalyzed by UGT1A9 and UGT2B7.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167566     DOI: 10.1124/dmd.30.9.1005

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  60 in total

Review 1.  Can pharmacogenomics improve malaria drug policy?

Authors:  Mary W Roederer; Howard McLeod; Jonathan J Juliano
Journal:  Bull World Health Organ       Date:  2011-09-01       Impact factor: 9.408

2.  Is there a differential conversion of artesunate to dihydroartemisinin in pregnant vs. post-partum patients with malaria after oral artesunate dosing?

Authors:  Nuggehally R Srinivas
Journal:  Br J Clin Pharmacol       Date:  2015-12-01       Impact factor: 4.335

3.  Predicting the Disposition of the Antimalarial Drug Artesunate and Its Active Metabolite Dihydroartemisinin Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Ryan Arey; Brad Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

Review 5.  Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals.

Authors:  Tony K L Kiang; Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

6.  Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.

Authors:  Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

7.  Treatment with coartem (artemether-lumefantrine) in Papua New Guinea.

Authors:  Sonja Schoepflin; Enmoore Lin; Benson Kiniboro; Jeana T DaRe; Rajeev K Mehlotra; Peter A Zimmerman; Ivo Mueller; Ingrid Felger
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

8.  Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients.

Authors:  Carrie A Morris; Beesan Tan; Stephan Duparc; Isabelle Borghini-Fuhrer; Donald Jung; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 9.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

10.  Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.

Authors:  Ann K Miller; Nibedita Bandyopadhyay; Daniel G Wootton; Stephan Duparc; Paula L Kirby; Peter A Winstanley; Stephen A Ward
Journal:  Eur J Clin Pharmacol       Date:  2009-06-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.